Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Rage in Brazil

Mass protests erupt in the biggest cities of Brazil.  Slideshow 

Photo

The Afghan Army

The many faces of the Afghan National Army, which has taken over security of the country from NATO.  Slideshow 

Sponsored Links

Repackaged Avastin caused eye infections in Florida

Related Topics

A worker makes its way on a bridge at Swiss pharmaceutical company Roche plant in Basel February 2, 2011. REUTERS/Christian Hartmann

A worker makes its way on a bridge at Swiss pharmaceutical company Roche plant in Basel February 2, 2011.

Credit: Reuters/Christian Hartmann

CHICAGO | Wed Aug 31, 2011 8:57am EDT

CHICAGO (Reuters) - Repackaged injections of the cancer drug Avastin, also known as bevacizumab, have caused a cluster of serious eye infections in the Miami, Florida area, the Food and Drug Administration said on Wednesday.

The Florida Department of Health notified the FDA of Streptococcus endophthalmitis infections in three clinics following injections given through the eye of repackaged Avastin, manufactured by Roche Holdings.

Investigators traced the tainted injections to a single pharmacy located in Hollywood, Florida. The pharmacy repackaged the Avastin from sterile injectable 100 mg/4 mL, single-use, preservative-free vials into individual 1 mL single-use syringes.

The pharmacy then distributed the Avastin to multiple eye clinics.

The FDA said it is aware of at least 12 patients in at least three of these clinics who had eye infections. While all of the patients had visual deficits prior to their injections with Avastin, some of these patients lost all remaining vision in that eye due to the endophthalmitis.

The agency and Florida health officials continue to investigate.

(Reporting by Debra Sherman, editing by Dave Zimmerman)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.